Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GST044
MIFTS: 56

Gastritis

Categories: Gastrointestinal diseases, Immune diseases, Infectious diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gastritis

About this section

MalaCards integrated aliases for Gastritis:

Name: Gastritis 12 29 54 6 43 15 62 17 71
Acute Gastric Mucosal Erosion 12 71
Erosive Gastropathy 12 71
Erosive Gastritis 12 71
Idiopathic Erosive/hemorrhagic Gastritis 71
Gastritis Erosive 54

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Gastrointestinal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4029
MeSH 43 D005756
NCIt 49 C26780
SNOMED-CT 67 4556007
ICD10 32 K29.7
UMLS 71 C0017152 C0267112 C2243088 more
Sources

Summaries for Gastritis

About this section
PubMed Health : 62 About gastritis: The membranes lining the stomach wall protect it from acid and germs. If this protective lining is irritated or damaged, it can become inflamed. Long-lasting inflammations can further damage the stomach lining and lead to stomach (gastric) ulcers. Inflammation of the stomach lining is called gastritis. It is usually caused by certain bacteria or anti-inflammatory medication. There are two kinds of gastritis: acute and chronic. Acute gastritis is typically accompanied by very noticeable stomach and bowel problems that usually go away again on their own after a few days. Chronic gastritis, on the other hand, sometimes goes unnoticed. People may only realize they have it when complications like stomach ulcers arise.

MalaCards based summary : Gastritis, also known as acute gastric mucosal erosion, is related to autoimmune atrophic gastritis and gastritis, familial giant hypertrophic, and has symptoms including dyspepsia and gastric irritation. An important gene associated with Gastritis is GAST (Gastrin), and among its related pathways/superpathways are Innate Immune System and Toll-Like receptor Signaling Pathways. The drugs Sucralfate and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and t cells.

Disease Ontology : 12 A stomach disease that is an inflammation of the lining of the stomach.

Wikipedia : 74 Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a... more...

Sources

Related Diseases for Gastritis

About this section

Diseases in the Gastritis family:

Autoimmune Gastritis Viral Gastritis
Bacterial Gastritis

Diseases related to Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 760)
# Related Disease Score Top Affiliating Genes
1 autoimmune atrophic gastritis 34.9 GAST CHGA
2 gastritis, familial giant hypertrophic 34.7 TFF2 MUC6 GAST
3 autoimmune gastritis 34.5 TFF2 IL1B GAST
4 atrophic gastritis 33.9 TFF2 S100A8 PTGS2 PGC PGA5 PGA4
5 helicobacter pylori infection 33.1 S100A8 MUC6 IL1B GAST CXCL8 CXCL1
6 gastroduodenitis 32.3 S100A8 GAST
7 gastrointestinal ulceration, recurrent, with dysfunctional platelets 32.2 S100A8 PTGS2 HRH2 GAST
8 bile reflux 32.0 S100A8 PTGS2 GAST
9 stomach disease 31.9 TLR4 TFF2 S100A8 PTGS2 PGC MUC6
10 esophagitis 31.7 PTGS2 IL1B HRH2 GAST CXCL8
11 peptic ulcer disease 31.7 S100A8 PTGS2 IL1RN IL1B HRH2 GHRL
12 gastric ulcer 31.7 TFF2 S100A8 PTGS2 IL1RN IL1B HRH2
13 crohn's disease 31.5 TLR4 S100A8 IL1B CXCL8
14 duodenal ulcer 31.5 TLR4 S100A8 IL1RN IL1B HRH2 GAST
15 microinvasive gastric cancer 31.5 TFF2 S100A8 MUC6 GAST
16 gastric adenocarcinoma 31.4 S100A8 PTGS2 NOS2 IL1RN IL1B GAST
17 celiac disease 1 31.4 TLR4 IL1B GHRL GAST CXCL8
18 zollinger-ellison syndrome 31.3 HRH2 GAST CHGA
19 peptic esophagitis 31.3 S100A8 PTGS2 IL1B HRH2 GAST CXCL8
20 peritonitis 31.2 TLR4 NOS2 IL1B CXCL8
21 colitis 31.2 TLR4 PTGS2 NOS2 IL1B DEFA5 CXCL8
22 ulcerative colitis 31.2 TLR4 IL1RN IL1B CXCL8
23 gastroenteritis 31.2 IL1RN IL1B HRH2 CXCL8
24 portal hypertension 31.1 TLR4 NOS2 CXCL8
25 diarrhea 31.1 TLR4 IL1B HRH2 GAST CXCL8 CXCL1
26 proteasome-associated autoinflammatory syndrome 1 31.1 TLR4 PTGS2 NOS2 IL1RN IL1B CXCL8
27 toxic shock syndrome 31.0 TLR4 NOS2 IL1RN IL1B CXCL8
28 barrett esophagus 31.0 TFF2 PTGS2 MUC6 GAST
29 hernia, hiatus 31.0 HRH2 GHRL GAST
30 cholecystitis 31.0 TLR4 S100A8 MUC6
31 stomatitis 31.0 TLR4 IL1RN IL1B CXCL8
32 crohn's colitis 31.0 NOS2 IL1B DEFA5 CXCL8
33 exanthem 31.0 IL1RN IL1B CXCL8
34 gastroesophageal reflux 31.0 S100A8 PTGS2 PGC IL1RN IL1B HRH2
35 gastric cancer 31.0 TLR4 TFF2 S100A8 PTGS2 PGA5 PGA4
36 carcinoid tumors, intestinal 30.9 GAST CHGA
37 neutropenia 30.9 TLR4 IL1RN IL1B CXCL8
38 acute pancreatitis 30.9 TLR4 IL1RN IL1B CXCL8
39 gastric neuroendocrine neoplasm 30.9 GAST CHGA
40 postgastrectomy syndrome 30.9 GHRL GAST
41 duodenal gastrinoma 30.9 HRH2 GAST CHGA
42 amebiasis 30.8 TLR4 IL1B CXCL8
43 dysentery 30.8 TLR4 IL1B CXCL8
44 pharyngitis 30.8 PTGS2 IL1RN IL1B CXCL8
45 periodontitis 30.8 TLR4 PTGS2 IL1RN IL1B DEFB1 CXCL8
46 irritable bowel syndrome 30.8 TLR4 IL1B GHRL CXCL8
47 candidiasis 30.7 TLR4 IL1B DEFB1 CXCL8
48 constipation 30.7 PTGS2 NOS2 GHRL GAST CHGA
49 bronchopneumonia 30.7 TLR4 IL1B CXCL8
50 pericarditis 30.7 IL1RN IL1B CXCL8

Graphical network of the top 20 diseases related to Gastritis:



Diseases related to Gastritis
Sources

Symptoms & Phenotypes for Gastritis

About this section

UMLS symptoms related to Gastritis:


dyspepsia, gastric irritation
Sources

Drugs & Therapeutics for Gastritis

About this section

PubMed Health treatment related to Gastritis: 62

If you notice that stress , alcohol or nicotine affect your symptoms, you can try to change your diet, stop drinking alcohol, quit smoking and reduce stress in everyday life. If these lifestyle changes are not enough to relieve the symptoms, medication is considered. Gastritis not caused by Helicobacter pylori is usually treated with medication to lower acid levels. Depending on the type and severity of the symptoms, the following drugs can be used: Proton pump inhibitors (PPIs) like omeprazole or pantoprazole reduce the production of stomach acid. H2 blockers such as ranitidine and famotidine also reduce acid production. Antacids like aluminium hydroxide or magnesium hydroxide neutralize the acid already in your stomach . If the gastritis is caused by a Helicobacter infection and is accompanied by noticeable symptoms, it will be treated using a combination of two or three antibiotics and an acid-lowering proton pump inhibitor . If the gastritis is caused by an NSAID painkiller, it is a good idea to consult your doctor about switching to a different painkiller or combining it with an acid-lowering medication. Should an NSAID have to be taken regularly, it is possible to take it along with acid-lowering medication from the start, as a precaution.

Drugs for Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sucralfate Approved Phase 4 54182-58-0
2
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
3
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
4
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965 14956
5
Ethanol Approved Phase 4 64-17-5 702
6
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
7
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
9
Titanium dioxide Approved Phase 4 13463-67-7
10
Sodium citrate Approved, Investigational Phase 4 68-04-2
11
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
12
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
13
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
14
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Azithromycin Approved Phase 4 83905-01-5 447043 55185
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
19
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
20
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
21
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
24
Rebamipide Investigational Phase 4 90098-04-7
25
Cobalamin Experimental Phase 4 13408-78-1 6857388
26
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
27
Sulforaphane Investigational Phase 4 142825-10-3, 4478-93-7 5350
28 Geranylgeranylacetone Phase 4
29 Antioxidants Phase 4
30 Vitamin B 12 Phase 4
31 Liposomal amphotericin B Phase 4
32 Vitamin B12 Phase 4
33 Norgestimate, ethinyl estradiol drug combination Phase 4
34 Acidophilus Phase 4
35 Bifidobacterium Phase 4
36 Citrate Phase 4
37 Anti-Infective Agents, Local Phase 4
38 Respiratory System Agents Phase 4
39 Antiprotozoal Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Cytochrome P-450 CYP3A Inhibitors Phase 4
42 Expectorants Phase 4
43 diuretics Phase 4
44 Antitubercular Agents Phase 4
45 Antimalarials Phase 4
46 Monoamine Oxidase Inhibitors Phase 4
47 Protective Agents Phase 4
48 Sulforafan Phase 4
49 Hormone Antagonists Phase 4
50 Hormones Phase 4

Interventional clinical trials:

(show top 50) (show all 303)
# Name Status NCT ID Phase Drugs
1 Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori Unknown status NCT01922765 Phase 4 amoxicillin, clarithromycin, metronidazole, rabeprazole
2 Community-based Helicobacter Pylori Eradication With Two Sequential Antibiotic Regimens for the Residents and Migrants From a High-risk Area for Gastric Cancer Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
3 Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study Unknown status NCT03130452 Phase 4 Lansoprazole 30mg;Amoxicillin 1.0g Tab;Clarithromycin 500mg;Metronidazole 500 mg
4 A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children Unknown status NCT03299725 Phase 4 colloidal bismuth sub-citrate
5 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
6 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
7 Effectiveness of Low Level Laser at the Auriculotherapy Points, in Reducing Postoperative Pain in Third Molar Surgery Unknown status NCT02657174 Phase 4
8 Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
9 Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study Unknown status NCT02134405 Phase 4 Rebamipide;Placebo (for Esomeprazole);Esomeprazole
10 A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis Completed NCT01284647 Phase 4 Teprenone capsule and placebo of sucralfate;Sucralfate and placebo of teprenone
11 A Multiple-center, Self-controlled Open Study to Evaluate Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer Completed NCT01190657 Phase 4 Selbex;Selbex
12 Clinical Effect of Rebamipide on Chronic Gastritis Completed NCT02393430 Phase 4 Rebamipide
13 A Phase IV Study to Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis Completed NCT01474044 Phase 4 Gastropylor Complex Capsules
14 A Phase 4, Multicenter, Randomized, Open, Active Drug Comparative Trial to Evaluated the Efficacy and Safety of EUPASIDIN-S Tab. in Gastritis Patients Completed NCT02356679 Phase 4 Eupasidin-s Tab;Stillen Tab.
15 A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis Completed NCT01817556 Phase 4 Stillen Tab.;Mucosta Tab.
16 A Multicenter, Randomized, Open-label Phase IV Study Exploring Symptom Control Rate in Co-diagnosed NERD and Chronic Gastritis Patients Treated With 8 Weeks Esomeprazole Treatment Regimen and 2 Weeks Esomeprazole Treatment Regimen Completed NCT01119768 Phase 4 Esomeprazole;Esomeprazole
17 Helicobacter Pylori Eradication With Clostridum Butyricum Capsule and Bacillus Coagulans Tablets Completed NCT03857425 Phase 4 Clostridum Butyricum Capsule;Bacillus Coagulans Tablets;Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets
18 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
19 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
20 Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori Completed NCT02873065 Phase 4 Ilaprazole;Esoprazole
21 Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy Completed NCT01792700 Phase 4 esomeprazole;tripotassium dicitrate bismuthate;metronidazole;tetracycline;moxifloxacin;amoxicillin
22 Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection Completed NCT02835560 Phase 4 Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy;Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy
23 Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea Completed NCT02401477 Phase 4 Ilaprazole + Amoxicillin
24 Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase â…£ Trial Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
25 Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients Completed NCT01888237 Phase 4 Double dose of PPI;sequence of drug use
26 Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase â…£ Trail Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
27 An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
28 Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection Completed NCT02541786 Phase 4 dexlansoprazole based triple therapy;rabeprazole-based triple therapy
29 Evaluation of Patients With Non-cardiac Chest Pain Using PillCam Eso - a Wireless Imaging Capsule of the Esophagus. Completed NCT00476398 Phase 4
30 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02490839 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
31 Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study Completed NCT02483715 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
32 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
33 Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication - A Prospective, Comparative Study Completed NCT01163435 Phase 4 high dose dual therapy;sequential therapy;clarithromycin-based triple therapy;levofloxacin-based triple therapy
34 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
35 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
36 Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
37 Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection Completed NCT02175927 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Metronidazole;Amoxicillin;Tetracycline
38 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy Completed NCT03609892 Phase 4 Berberine;Amoxicillin;Esomeprazole;Bismuth;Tetracycline;Furazolidone;Esomeprazole;Bismuth
39 A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain: A Randomized Control Trial Completed NCT03221946 Phase 4 Diclofenac Sodium;Diclofenac sodium;Diclofenac
40 Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial Completed NCT04039412 Phase 4 Hybrid regimen;Reverse hybrid regimen;Levofloxacin quadruple regimen
41 Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia Completed NCT00951431 Phase 4 Esomeprazole;Placebo
42 Effects of Esomeprazole on Gastric Emptying of Alcoholic Beverages, Blood Alcohol Concentrations, Gastroesophageal Reflux and Release of Some Gastrointestinal Hormones in Healthy Volunteers Completed NCT00472550 Phase 4 esomeprazole 20 mg
43 Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Recruiting NCT02175186 Phase 4 ALBIS;Placebo
44 Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality Recruiting NCT02047994 Phase 4 Triple therapy
45 A Randomized Controlled Trial of Triple Therapy With Conventional Proton Pump Inhibitor vs Triple Therapy With Vonoprazan as First Line Therapy for Helicobacter Pylori Gastritis Recruiting NCT03908619 Phase 4 Omeprazole 20mg;Esomeprazole 20mg;Rabeprazole Sodium 20mg;Vonoprazan
46 The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study Recruiting NCT03342456 Phase 4 Doxycycline Hyclate Enteric-Coated Capsules;Amoxicillin Capsules;Ilaprazole Enteric-Coated Tablets;Furazolidone Tablets;Potassium Citrate Tablets
47 Efficacies of High-dose Dual Therapy With or Without Bismuth Versus Amoxicillin-metronidazole Bismuth Quadruple Therapy for First-line Helicobacter Pylori Eradication - A Prospective, Randomized, Comparative Study Recruiting NCT03897244 Phase 4 High-dose dual therapy (rabeprazole, amoxicillin);Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate);Amoxicillin-Metronidazole Bismuth quadruple therapy
48 10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial Recruiting NCT03592069 Phase 4 10 day concomitant regimen;14 day hybrid regimen
49 The Effect of Broccoli Sprout Extract and Probiotics on Proton Pump Inhibitor-based Triple Therapy for Eradication of Helicobacter Pylori: a Prospective Randomized Trial Active, not recruiting NCT03220542 Phase 4 Probiotics;Esomeprazole;Amoxicillin;Clarithromycin
50 The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study Not yet recruiting NCT02933229 Phase 4 H. pylori eradication

Search NIH Clinical Center for Gastritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cat's Claw preparation
Sucralfate

Cochrane evidence based reviews: gastritis

Sources

Genetic Tests for Gastritis

About this section

Genetic tests related to Gastritis:

# Genetic test Affiliating Genes
1 Gastritis 29
Sources

Anatomical Context for Gastritis

About this section

MalaCards organs/tissues related to Gastritis:

40
Testes, Colon, T Cells, Liver, Thyroid, B Cells, Neutrophil
Sources

Publications for Gastritis

About this section

Articles related to Gastritis:

(show top 50) (show all 21507)
# Title Authors PMID Year
1
Defensin-mRNA expression in the upper gastrointestinal tract is modulated in children with celiac disease and Helicobacter pylori-positive gastritis. 61 54
20400909 2010
2
Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. 54 61
20026064 2010
3
Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. 54 61
20302630 2010
4
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion. 54 61
19711347 2010
5
Interleukin 1 beta (IL1B) gene polymorphisms are not associated with gastric carcinogenesis in Germany. 61 54
20332462 2010
6
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 54 61
20038850 2010
7
TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. 61 54
20332463 2010
8
[Quantification of cyclooxygenase-2 methylation in gastric mucosa by denaturing high performance liquid chromatography assay]. 61 54
20388365 2010
9
Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin and VCAM-1. 61 54
19812370 2009
10
Gastric ghrelin in relation to gender, stomach topography and Helicobacter pylori in dyspeptic patients. 54 61
19916170 2009
11
RANTES promoter genotype and gastric cancer risk in a Japanese population. 61 54
19846984 2009
12
homB status of Helicobacter pylori as a novel marker to distinguish gastric cancer from duodenal ulcer. 61 54
19710266 2009
13
Antibodies to Helicobacter pylori and CagA protein are associated with the response to antibacterial therapy in patients with H. pylori-positive API2-MALT1-negative gastric MALT lymphoma. 61 54
19385974 2009
14
Transforming growth factor-B1 and matrix metalloproteinase-7 promoter variants induce risk for Helicobacter pylori-associated gastric precancerous lesions. 54 61
19317620 2009
15
A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence. 54 61
19262506 2009
16
Remnant gastritis should be evaluated histologically rather than endoscopically. 54 61
19621726 2009
17
Serum antibodies positivity to 12 Helicobacter pylori virulence antigens in patients with benign or malignant gastroduodenal diseases--cross-sectional study. 61 54
19399945 2009
18
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
19
Gender difference of circulating ghrelin and leptin concentrations in chronic Helicobacter pylori infection. 54 61
19191897 2009
20
The relationship between virulence factors of Helicobacter pylori and severity of gastritis in infected patients. 61 54
18465229 2009
21
Cross-talk between inducible nitric oxide synthase and cyclooxygenase in Helicobacter-pylori-induced gastritis. 54 61
19797925 2009
22
Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. 54 61
18985541 2009
23
Prevalence of Helicobacter pylori pathogenicity-associated cagA and vacA genotypes among Pakistani dyspeptic patients. 61 54
19040660 2009
24
Decreased TFF2 expression in the gastric antrum in patients infected with CagA-positive Helicobacter pylori. 54 61
19344006 2009
25
Iron deficiency, Helicobacter infection and gastritis. 61 54
19907146 2009
26
[Dynamics of pro-and anti-inflammatory cytokines at patients with combination of chronic opisthorchiasis with Helicobacter pylori-associated gastritis]. 54 61
19551959 2009
27
Role of cyclooxygenase-2 functional gene polymorphisms in Helicobacter pylori induced gastritis and gastric atrophy. 61 54
18825488 2009
28
Potential role of human beta-defensin 1 in Helicobacter pylori-induced gastritis. 54 61
18991164 2009
29
Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells. 61 54
18775915 2008
30
Presence of poorly differentiated component correlated with submucosal invasion in the early diffuse-type gastric cancer. 54 61
19260519 2008
31
The long-term effect of Helicobacter pylori eradication on COX-1/2, 5-LOX and leukotriene receptors in patients with a risk gastritis phenotype--a link to gastric carcinogenesis. 61 54
18571838 2008
32
cagA, vacA, and iceA genotypes of Helicobacter pylori in Korean children. 61 54
19261108 2008
33
Helicobacter pylori infection induces a reversible expression of the CDX2 transcription factor protein in human gastric epithelium. 61 54
19086163 2008
34
Serum gastrin concentration and changes in G and D cell densities in gastric antrum in children with chronic gastritis. 61 54
17573842 2008
35
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 54 61
18653971 2008
36
The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea. 54 61
18321304 2008
37
Four modes of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches. 61 54
18321298 2008
38
Toll-like receptor 2 (TLR) -196 to 174del polymorphism in gastro-duodenal diseases in Japanese population. 54 61
17934843 2008
39
T-251A polymorphism of IL-8 relating to the development of histological gastritis and G-308A polymorphism of TNF-alpha relating to the development of macroscopic erosion. 54 61
18301299 2008
40
Expression of 8-hydroxydeoxyguanosine in the gastric remnant after distal gastrectomy. 54 61
18613397 2008
41
Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. 61 54
18299465 2008
42
IL-4 -588C>T polymorphism and IL-4 receptor alpha [Ex5+14A>G; Ex11+828A>G] haplotype concur in selecting H. pylori cagA subtype infections. 61 54
18179773 2008
43
Autoimmune gastritis in type 1 diabetes: a clinically oriented review. 61 54
18029461 2008
44
Serum pepsinogen I, pepsinogen II, and gastrin 17 in relatives of gastric cancer patients: comparative study with type and severity of gastritis. 54 61
18237867 2008
45
Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis? 54 61
18047563 2008
46
Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. 54 61
18004396 2007
47
Microevolution of Helicobacter pylori type IV secretion systems in an ulcer disease patient over a ten-year period. 54 61
17942650 2007
48
Serum ghrelin as a marker of atrophic body gastritis in patients with parietal cell antibodies. 54 61
17711921 2007
49
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 54 61
17922404 2007
50
Emerging role of IL-23/IL-17 axis in H pylori-associated pathology. 61 54
17948927 2007
Sources

Variations for Gastritis

About this section

ClinVar genetic disease variations for Gastritis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CEL NM_001807.5(CEL):c.1966G>C (p.Ala656Pro)SNV Uncertain significance 128688 rs587780309 9:135946855-135946855 9:133071468-133071468
Sources

Expression for Gastritis

About this section
Search GEO for disease gene expression data for Gastritis.
Sources

Pathways for Gastritis

About this section

Pathways related to Gastritis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.91 TLR4 S100A8 PTGS2 NOS2 MUC6 IL1RN
2
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.59 TLR4 PTGS2 NOS2 IL1RN IL1B CXCL8
3
Defensins 65
Show member pathways
 12.24 S100A8 DEFB1 DEFA5 CHGA
4
Toll Comparative Pathway 63
Show member pathways
 12.2 TLR4 PTGS2 NOS2 IL1B CXCL8
5
IL-17 Family Signaling Pathways 64
Show member pathways
 12.19 S100A8 PTGS2 IL1B CXCL8 CXCL1
6
Toxoplasmosis 36
Show member pathways
 12.18 TLR4 PTGS2 NOS2 IL1B
7
Bacterial infections in CF airways 22
Show member pathways
 12.09 TLR4 NOS2 IL1B CXCL8
8
NOD-like receptor signaling pathway 36
12.06 TLR4 IL1B DEFA5 CXCL8 CXCL1
9
Interleukin-4 and 13 signaling 65
11.88 PTGS2 NOS2 IL1B CXCL8
10
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.76 TLR4 CXCL8 CXCL1
11
Rheumatoid arthritis 36
11.76 TLR4 IL1B CXCL8 CXCL1
12
NF-kappa B signaling pathway 36
11.67 TLR4 PTGS2 IL1B CXCL8 CXCL1
13
Pertussis 36
11.61 TLR4 NOS2 IL1B CXCL8
14
Amoebiasis 36
11.56 TLR4 NOS2 IL1B CXCL8 CXCL1
15
Hepatitis C and Hepatocellular Carcinoma 1
11.48 PTGS2 NOS2 CXCL8
16
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.47 PTGS2 NOS2 IL1B CXCL8
17
Malaria 36
11.46 TLR4 IL1B CXCL8
18
MSP-RON Signaling 63
11.42 TLR4 NOS2 IL1B
19
Legionellosis 36
11.38 TLR4 IL1B CXCL8 CXCL1
20
Surfactant metabolism 65
Show member pathways
 11.36 PGA5 PGA4 PGA3
21
Spinal Cord Injury 1
11.18 TLR4 PTGS2 NOS2 IL1B CXCL8 CXCL1
22
Interleukin-10 signaling 65
11.04 PTGS2 IL1RN IL1B CXCL8 CXCL1
23
Gastric acid production 1
10.45 MUC6 GAST
24
Secretion of Hydrochloric Acid in Parietal Cells 1
10.27 HRH2 GAST
Sources

GO Terms for Gastritis

About this section

Cellular components related to Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 TFF2 S100A8 PGC IL1RN IL1B GHRL
2 extracellular region GO:0005576 9.53 TFF2 S100A8 PGC PGA5 PGA4 PGA3
3 multivesicular body lumen GO:0097486 9.33 PGA5 PGA4 PGA3

Biological processes related to Gastritis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.91 PTGS2 NOS2 IL1RN IL1B CXCL8 CXCL1
2 immune response GO:0006955 9.91 TLR4 IL1RN IL1B HRH2 DEFB1 CXCL8
3 chemotaxis GO:0006935 9.88 S100A8 DEFB1 CXCL8 CXCL1
4 response to lipopolysaccharide GO:0032496 9.88 TLR4 S100A8 PTGS2 NOS2 IL1B
5 defense response GO:0006952 9.87 DEFB1 DEFA5 CXCL8 CXCL1
6 neutrophil chemotaxis GO:0030593 9.81 S100A8 IL1B CXCL8 CXCL1
7 positive regulation of inflammatory response GO:0050729 9.8 TLR4 S100A8 IL1B
8 regulation of inflammatory response GO:0050727 9.8 TLR4 S100A8 PTGS2
9 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.8 DEFB1 DEFA5 CXCL8 CXCL1
10 defense response to bacterium GO:0042742 9.8 TLR4 S100A8 NOS2 DEFB1 DEFA5 CHGA
11 cellular response to mechanical stimulus GO:0071260 9.79 TLR4 PTGS2 IL1B
12 chemokine-mediated signaling pathway GO:0070098 9.78 TFF2 CXCL8 CXCL1
13 antimicrobial humoral response GO:0019730 9.76 S100A8 DEFB1 DEFA5 CHGA
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 TLR4 PTGS2 IL1B
15 defense response to fungus GO:0050832 9.71 S100A8 DEFA5 CHGA
16 protein catabolic process GO:0030163 9.71 PGC PGA5 PGA4 PGA3
17 innate immune response in mucosa GO:0002227 9.7 NOS2 DEFB1 DEFA5
18 maintenance of gastrointestinal epithelium GO:0030277 9.63 TFF2 MUC6
19 negative regulation of blood vessel diameter GO:0097756 9.61 PTGS2 CHGA
20 gastric acid secretion GO:0001696 9.6 HRH2 GHRL
21 positive regulation of prostaglandin biosynthetic process GO:0031394 9.59 PTGS2 IL1B
22 positive regulation of fever generation GO:0031622 9.58 PTGS2 IL1B
23 digestion GO:0007586 9.56 PGC PGA5 PGA4 PGA3
24 peptidyl-cysteine S-nitrosylation GO:0018119 9.55 S100A8 NOS2
25 defense response to Gram-negative bacterium GO:0050829 9.55 TLR4 NOS2 DEFB1 DEFA5 CHGA
26 cellular response to lipopolysaccharide GO:0071222 9.43 TLR4 NOS2 IL1B DEFA5 CXCL8 CXCL1
27 inflammatory response GO:0006954 9.23 TLR4 S100A8 PTGS2 NOS2 IL1RN IL1B

Molecular functions related to Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CXCR chemokine receptor binding GO:0045236 9.26 CXCL8 CXCL1
2 cytokine activity GO:0005125 9.26 IL1RN IL1B CXCL8 CXCL1
3 interleukin-1 receptor binding GO:0005149 9.16 IL1RN IL1B
4 aspartic-type endopeptidase activity GO:0004190 8.92 PGC PGA5 PGA4 PGA3
Sources

Sources for Gastritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....